DENVER, Colo. - The International Association for the Study of Lung Cancer's (IASLC) Strategic Screening Advisory Committee will hold the Third CT Screening Workshop on Saturday, Sept. 5 at 9 a.m. at the Colorado Convention Center, Rooms 708+710+712, prior to the official opening of the 16th Annual World Conference on Lung Cancer (WCLC). International leaders in computed tomography (CT) screening from across the world, including Japan, Australia, Canada, Europe and the U.S., are set to participate.
CT screening is more important than ever. The World Health Organization reports there were 1.8 million new lung cancer cases worldwide in 2012 and the American Cancer Society estimates 158,000 Americans will die from lung cancer in 2015. There are more deaths from lung cancer than the combined figures from breast, colon and prostate cancers.
This CT Screening Workshop will discuss several major advances in lung cancer screening:
- The new CT screened nodule guidelines from the NELSON trial and the British Thoracic Society;
- Quality control for future screening programs;
- Cost-effectiveness modeling and how to select high-risk patients, using risk-prediction modeling, for future programs;
- Use of validated biomarkers of early disease to provide new data for clinical investigators to consider whether this approach will help identify high-risk subgroups for future lung cancer screening.
"The future lies in early detection and currently this is only practical using a special type of X-ray called Low Dose Computed Tomography (LDCT)," said Professor John Field, Chair of the IASLC Screening Advisory Committee and Personal Clinical Chair in Molecular Oncology at the University of Liverpool.
Professor Field pointed out that a landmark lung cancer screening trial in the U.S. in 2011, the National Lung Screening Trial (NLST), demonstrated a 20 percent mortality advantage in individuals in the CT screened arm.
Additionally, the workshop will focus on the status of the national plans for implementing lung cancer CT screening across the globe. Many clinicians focus on organizing screening programs to overcome barriers that are holding back CT screening efforts.
"The Third CT Screening Workshop will provide an overview of current advances in lung cancer screening as well as providing a forum to discuss the issues and barriers to setting up lung cancer screening programs outside the U.S. It is imperative we take this initiative forward internationally, as CT screening together with integrated smoking cessation programs are the only methods we have available to reduce the burden of lung cancer," Professor Field said.
"We know from previous screening efforts that whatever potential benefit screening may allow, this benefit can be lost through poorly-delivered screening services. This IASLC workshop is a great opportunity to share international best practice, so as screening is being implemented in new settings, the quality of the care embeds measures that have been carefully vetted for this new process," said Dr. Jim Mulshine, a committee member and Dean (Acting), Graduate College and Vice President at Rush University in Chicago, Ill.
"Although the exciting increased survival in advanced disease upon the progress in targeted- and immune- therapies, efficient screening may save thousands of lives and must be implemented around the globe," added Professor Nir Peled, chair of the IASLC Prevention & Screening committee and the head of the Thoracic Cancer Unit at Davidoff Cancer Center, Tel Aviv University, Israel.
About the WCLC:
The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The conference goal is to increase awareness and collaboration so that the latest developments in lung cancer can be understood and implemented throughout the world. Falling under the theme of "Fighting Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For the first time, IASLC is including patients in the conference free of charge.
General and Media registration is now open. For more information, visit: http://wclc2015.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization specifically dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,000 lung cancer specialists in more than 90 countries. For more information, visit: https:/